7 docs tagged with "indian-stocks"

India's premium telecom duopoly leader with strong ARPU-led growth and improving deleveraging, but trading at a steep valuation premium to peers.

Fundamental analysis of Cipla - India's

Fundamental analysis of Divi's Laboratories - India's largest API/CDMO player and a China+1 and GLP-1 peptide beneficiary, trading at an extremely rich valuation.

Fundamental analysis of Dr. Reddy's Laboratories - biosimilars and GLP-1 pipeline against the backdrop of a semaglutide API quality miss and securities-fraud investigation.

India's dominant low-cost carrier with a record 66% domestic market share, but FY26 swung to a net loss on fuel and forex — moat intact, near-term earnings volatile.

Fundamental analysis of Lupin - the sector's best growth-plus-valuation combination, with US complex-generics/respiratory momentum and an India recovery, at the cheapest PE among large-cap Indian pharma peers.

India's largest pharma company by market cap - fundamental analysis covering specialty portfolio scaling, US generics decline, Halol FDA import alert, and valuation.